Identifying and Treating Delayed-Onset Filler Nodules

When a patient presents months or years after filler treatment with a new lump, bump, or area of swelling, it can be tempting to classify the finding simply as a delayed-onset filler nodule. However, a nodule is a clinical finding; it is not a diagnosis.

What appears to be a delayed filler complication may reflect a range of distinct processes, from previously inconspicuous filler becoming visible after substantial weight loss to a transient inflammatory reaction or infection associated with biofilm. These distinctions are clinically important because appropriate management may range from observation to intralesional therapy, hyaluronidase, or prolonged antimicrobial treatment.

The challenge is to identify the underlying process to guide treatment.

WHEN WEIGHT LOSS REVEALS
WHAT WAS ALREADY THERE

With the growing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), patients are experiencing rapid and sometimes substantial facial volume loss. One consequence is that previously inconspicuous filler may suddenly become visible.

This is not necessarily a delayed inflammatory reaction. Loss of surrounding subcutaneous tissue may simply expose the contour or location of product that was previously camouflaged by a fuller face. Significant weight loss may also make facial veins and arteries more apparent.

The implications extend beyond appearance. In patients with a very low body mass index and reduced facial fat, less tissue may separate the skin from the underlying vasculature. This warrants additional caution with injection depth and technique because the vessels may be more superficial and therefore more vulnerable to injury.

When a new contour abnormality appears after weight loss, the first question should not automatically be, “Why is the filler reacting?” A more useful question may be, “Has anything happened to the filler, or can I simply see it now?”

INFLAMMATION, INFECTION, OR BOTH?

True inflammatory nodules present a more difficult diagnostic problem. The differential may include an immune-mediated foreign body response, infection associated with biofilm, and other delayed inflammatory processes. These mechanisms may overlap. A foreign body may potentially provide an environment in which microorganisms persist while also participating in the host inflammatory response.

The evidence supporting conventional allergy as the explanation for most late inflammatory reactions to hyaluronic acid (HA) is weak. Decates et al¹ performed intradermal testing in 12 patients with previous late inflammatory reactions using several HA fillers, and found no immediate or delayed positive reactions during 4 months of follow-up. The findings argue against routinely assuming a type I or type IV hypersensitivity mechanism with HA.

Biofilm presents a different diagnostic challenge. Conventional cultures may be negative even when microorganisms are involved (therefore, polymerase chain reaction [PCR] is recommended), and late tissue nodules associated with HA injections remain an area of uncertainty and debate. A multidisciplinary consensus published in 2023 emphasized the importance of distinguishing inflammatory from noninflammatory nodules and considering both infective and immune-mediated etiologies when determining treatment.²

The key point is that different causes can converge on a similar clinical endpoint: edema, tenderness, erythema, induration, and granulomatous nodules do not, by themselves, establish the underlying mechanism.

ARE GLP-1 RA MEDICATIONS
A NEW TRIGGER?

A particularly intriguing question is whether GLP-1 RA–based therapies can trigger delayed reactions at previous injectable-treatment sites.

A 2026 publication described a 66-year-old woman who developed facial nodules at sites previously treated with HA filler, calcium hydroxylapatite, and incobotulinumtoxinA after beginning compounded tirzepatide.³ The nodules reportedly improved after discontinuation of tirzepatide along with isotretinoin treatment and recurred following a subsequent dose increase. This observation is interesting but does not establish causality.

There are reasonable arguments on both sides. GLP-1 RA–based therapies have recognized immunologic effects, and rare cutaneous hypersensitivity and inflammatory adverse events have been reported.⁴ At the same time, GLP-1 RAs generally have systemic anti-inflammatory effects, including modulation of inflammatory signaling and cytokine pathways.⁵

There is also a simple statistical problem: GLP-1 RA therapies and aesthetic injectables are both extremely common. Inevitably, some patients taking GLP-1 RA medications will develop filler nodules for unrelated reasons.

The aforementioned 2026 case³ involved compounded tirzepatide, adding another variable, because excipients and formulation may differ from US Food and Drug Administration–approved products. Interestingly, substantial differences in immunogenicity have been reported between tirzepatide and semaglutide. Across 7 phase 3 trials, treatment-emergent antidrug antibodies developed in 51.1% of tirzepatide-treated participants, whereas antisemaglutide antibodies were detected in approximately 3% of participants treated with semaglutide 2.4 mg in the pivotal Wegovy trials, although the clinical significance of these antibodies remains uncertain.^6,7 For now, GLP-1 RA therapy with tirzepatide may be considered a potential trigger worth documenting, similar to other medications, but it should not be regarded as a proven cause of delayed filler nodules.

SOMETIMES, LESS TREATMENT REVEALS MORE

Clinical behavior over time can also clarify the underlying process.

In one case, a patient presented with a single acute, erythematous, tender, nonfluctuant nodule. Incision produced no drainage. A small intralesional injection of triamcinolone resulted in complete resolution within several days.

Another patient developed slowly enlarging, tender nodules at multiple sites months after filler treatment. Two lesions were treated with hyaluronidase, 5-fluorouracil, and triamcinolone, whereas a contralateral lesion was deliberately left untreated. All 3 resolved during the following month.

Cases like these underscore that spontaneous resolution can occur. When every lesion is treated aggressively, natural improvement may be incorrectly attributed to the intervention.

WHEN THE CLINICAL COURSE POINTS TOWARD INFECTION

Other cases behave very differently. One patient I treated initially developed a hard, noninflammatory nodule that became painful and fluctuant after treatment with a small dose of hyaluronidase. Standard culture was negative, but polymerase chain reaction testing was positive for Cutibacterium acnes. The patient experienced multiple relapses and ultimately required prolonged oral antibiotics followed by intravenous vancomycin.

The clinical context was particularly important. The patient was receiving pembrolizumab and had also received systemic and intra-articular corticosteroids. Pembrolizumab is an immune checkpoint inhibitor rather than a conventional immunosuppressant; however, high-dose corticosteroid use among patients receiving PD-1/PD-L1 inhibitors has been associated with a significantly increased risk of hospitalization for infection.⁸

This context should prompt caution before reflexively treating every inflammatory filler nodule with corticosteroids. If infection or biofilm is contributing to the process, suppressing the inflammatory response without addressing the infectious component may be counterproductive.

TREAT THE DIAGNOSIS,
NOT THE NODULE

Delayed-onset nodules require clinicians to resist pattern recognition without sufficient investigation. The same apparent “filler bump” may represent newly visible product following weight loss, a transient inflammatory process, an immune-mediated foreign body response, or infection. That distinction should guide both workup and treatment.

The practical lesson is straightforward: before reaching for hyaluronidase, corticosteroids, or antibiotics, clinicians should establish what they are treating and remain willing to revise that diagnosis if the clinical course does not behave as expected.

Disclosures: The author reported no relevant financial disclosures.